Bacterial sialadenitis is an infection and inflammation of a salivary gland caused by a bacterial infection, most commonly Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. The three pairs of major salivary glands that are commonly affected are the parotid, submandibular, and sublingual glands. The infection leads to symptoms like swelling of the affected salivary gland, pain in and around the gland, trouble swallowing or speaking, pus draining from the area, fever and sometimes toothache. Treatment involves antibiotics to treat the infection and pain medications to manage symptoms. If left untreated, it can lead to abscess formation requiring drainage. The growing prevalence of infectious diseases, increasing oral infections, and rising awareness about treatment are expected to drive the growth of the bacterial sialadenitis market over the forecast period.
Market key trends:
One of the key trends in the bacterial sialadenitis market is the development of novel antibiotic drugs with improved efficacy. With growing antibiotic resistance, there is a need for new antibiotics that can effectively treat bacterial infections. Companies are investing heavily in researching and developing novel classes of antibiotics targeting critical pathways in bacteria. Recently approved antibiotics with activity against pathogens that commonly cause bacterial sialadenitis include cefiderocol and ceftazidime-avibactam.
Another trend is the increasing adoption of minimally invasive procedures for drainage of abscesses caused by advanced bacterial sialadenitis. Minimally invasive techniques such as sialoendoscopy allow direct visualization and targeted drainage of abscesses, reducing trauma, risk of damage to surrounding tissues, scarring and post-procedure pain compared to conventional open drainage surgeries. This is expected to drive their increasing adoption over the forecast period.
The global Bacterial Sialadenitis Market Share is estimated to be valued at US$ 1.90 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Threat of new entrants: The threat of new entrants in the bacterial sialadenitis market is low due to high capital requirements and stringent regulatory barriers.
Bargaining power of buyers: The bargaining power of buyers in the bacterial sialadenitis market is moderate as the products in this market are differentiated with no substitutes available.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the availability of generic versions and substitute treatment options.
Threat of new substitutes: The threat of substitutes is low as there are limited treatment alternatives available for bacterial sialadenitis.
Competitive rivalry: High as the market is dominated by key global players.
The global bacterial sialadenitis market is expected to witness high growth, exhibiting a CAGR of 5.6% over the forecast period, due to the increasing prevalence of infectious diseases.
The North American region is expected to dominate the global bacterial sialadenitis market throughout the forecast period owing to increasing research & development activities and growing bacterial infections in the region.
Key players operating in the bacterial sialadenitis market are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Allergan plc.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it